KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.

Gwen Hua, Daniel Carlson, Jacqueline R Starr

J Adv Pract Oncol 13(7) 717-723

PMID36199496
PMCIDPMC9514125
DOI10.6004/jadpro.2022.13.7.8
发表日期2022-10-06
摘要

摘要

Uveal melanoma is the most common intraocular cancer in adults. Metastatic uveal melanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of T cell-directed therapy. Tebentafusp-tebn has been shown in a randomized phase III clinical trial to lead to improved overall survival and progression-free survival when compared with single-agent pembrolizumab, ipilimumab, or dacarbazine in previously untreated human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma patients. Tebentafusp-tebn is now approved by the US Food and Drug Administration in HLA-A*02:01-positive uveal melanoma patients as first-line therapy in the metastatic setting.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。